Patents Represented by Attorney, Agent or Law Firm David G. O'Brien
-
Patent number: 6733777Abstract: Cationic cytofectins and liposomes comprising the same are disclosed which are especially useful for delivering exogenous compounds into cells in vitro and in vivo. The liposomes may comprise (a) a neutral lipid such as dioleoylphosphatidyl-ethanolamine (DOPE) or similar lipid-like compounds such as 1,2-dioleoyl-oxiphosphatidylethanolamine or other lipid-like structures and (b) one or more of the cationic cytofectins provided herein. The invention provides transfection kits and methods for delivery of exogenous compounds into cells.Type: GrantFiled: May 4, 1999Date of Patent: May 11, 2004Assignee: Qiagen GmbHInventors: Christoph Erbacher, Martin Weber
-
Patent number: 6562829Abstract: A composition for treating hepatic fibrosis and a method of using and manufacturing the composition are provided. The composition includes a quinazolinone derivative, preferably Halofuginone.Type: GrantFiled: October 13, 1999Date of Patent: May 13, 2003Assignees: Hadasit Medical Research Services & Development Co., Ltd., Agricultural Research Organaization-Ministry of AgricultureInventors: Mark Pines, Arnon Nagler
-
Patent number: 6451260Abstract: Described are novel methods for producing microporous elements and microporous elements obtainable by such methods. Provided are also microporous elements including solid microparticles, which preferably modify the adsorptive properties of the microporous element. Described are also microporous elements which are linked to a support and/or a retainer as well as methods for their production. Filter elements comprising the above-described microporous elements are also provided. Furthermore, kits, diagnostic and pharmaceutical compositions comprising the aforementioned microporous or filter elements are described. Furthermore, uses of the aforementioned microporous and filter elements in microfiltration, chromatography, adsorption/immobilization of organic and inorganic compounds as well as for the preparation and/or detection of such compounds are disclosed.Type: GrantFiled: March 9, 1999Date of Patent: September 17, 2002Assignee: Dyax Corp.Inventors: Andreas Düsterhöft, Thomas Manz, Ehrenfried Mehl, Friedrich Lottspeich
-
Patent number: 6423498Abstract: This invention provides: novel proteins, which are homologous to the first Kunitz domain (K1) of lipoprotein-associated coagulation inhibitor (LACI), and which are capable of inhibiting plasmin; uses of such novel proteins in therapeutic, diagnostic, and clinical methods; and polynucleotides that encode such novel proteins.Type: GrantFiled: August 15, 2000Date of Patent: July 23, 2002Assignee: Dyax Corp.Inventors: William Markland, Robert Charles Ladner
-
Patent number: 6316604Abstract: The present invention relates to the C3b/C4b receptor (CR1) gene and its encoded protein. The invention also relates to CR1 nucleic acid sequences and fragments thereof comprising 70 nucleotides and their encoded peptides or proteins comprising 24 amino acids. The invention further provides for the expression of the CR1 protein and fragments thereof. The genes and proteins of the invention have uses in diagnosis and therapy of disorders involving complement activity, and various immune system or inflammatory disorders. In specific embodiments of the present invention detailed in the examples sections infra, the cloning, nucleotide sequence, and deduced amino acid sequence of a full-length CR1 cDNA and fragments thereof are described. The expression of the CR1 protein and fragments thereof is also described. Also described is the expression of a secreted CR1 molecule lacking a transmembrane region.Type: GrantFiled: June 5, 1995Date of Patent: November 13, 2001Assignee: Avant Immunotherapeutics, Inc.Inventors: Douglas T. Fearon, Lloyd B. Klickstein, Winnie W. Wong, Gerald R. Carson, Michael F. Concino, Stephen H. Ip, Savvas C. Makrides, Henry C. Marsh, Jr.
-
Patent number: 6197526Abstract: Methods for detecting human factor VIII or factor VIII-like polypeptides in and isolating it from solutions such as blood or conditioned media are disclosed, together with reagents suitable for the purpose comprising binding moieties that recognize human factor VIII and/or a factor VIII-like polypeptide and form a binding complex therewith. Preferred polypeptide binding moieties are particularly disclosed.Type: GrantFiled: January 4, 1999Date of Patent: March 6, 2001Assignees: Dyax Corp., Genetics Inst.Inventors: Jinan Yu, M. Daniel Potter, Brian D. Kelley, Jeffrey S. Deetz, James Edward Booth
-
Patent number: 6193979Abstract: The present invention provides compositions comprising at least one complement moiety and at least one carbohydrate moiety, and methods of producing such compositions. In particular, the compositions of the invention comprise complement proteins related to the complement receptor type 1, and further comprise ligands for intercellular molecules, such as selectins. In a preferred embodiment, the compositions comprise a complement-related protein in combination with the Lewis X antigen or the sialyl Lewis X antigen. The compositions of the invention have use in the diagnosis or therapy of disorders involving complement activity and inflammation. Pharmaceutical compositions are also provided for treating or reducing inflammation mediated by inappropriate complement activity and intercellular adhesion.Type: GrantFiled: May 25, 1995Date of Patent: February 27, 2001Assignee: Avant Immunotherapeutics, Inc.Inventors: Charles W. Rittershaus, Carol A. Toth
-
Patent number: 6183998Abstract: A method for the amplification of a target nucleic acid is disclosed comprising the steps of reacting a nucleic acid with an amplification reaction mixture and a modified thermostable enzyme, wherein said modified thermostable polymerase is prepared by a reaction of a mixture of a thermostable polymerase and a chemical modifying reagent. The chemical modification reagent is an aldehyde, preferably formaldehyde. Essentially complete inactivation of the enzyme at ambient temperatures is achieved, with recovery of enzymatic activity at temperatures above 50° C.Type: GrantFiled: October 31, 1998Date of Patent: February 6, 2001Assignee: Qiagen GmbH Max-Volmer-Strasse 4Inventors: Igor Ivanov, Dirk Löffert, Jie Kang, Joachim Ribbe, Kerstin Steinert